Actinium Pharmaceuticals (ATNM) Accounts Payables (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Accounts Payables of $6.6 million for Q1 2026, up 1.46% year-over-year from $6.5 million in Q1 2025, and down 8.72% quarter-over-quarter from $7.2 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Accounts Payables (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Accounts Payables for 15 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 1.46% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (up 1.46% YoY), while the FY2025 annual figure was $7.2 million, down 4.24% from the prior year.
- Accounts Payables slipped to $6.6 million in Q1 2026 per ATNM's latest filing, from $7.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $9.2 million in Q2 2024 and bottomed at $6.2 million in Q3 2025.
- Historically, Accounts Payables has averaged $7.4 million across 4 years, with a median of $7.2 million in 2025.
- Annual changes were most pronounced in 2025 — Accounts Payables decreased 15.94% — and 2026, when it grew 1.46%.
- Actinium Pharmaceuticals' Accounts Payables stood at $8.0 million in 2023, then dropped by 4.84% to $7.6 million in 2024, then fell by 4.24% to $7.2 million in 2025, then slipped by 8.72% to $6.6 million in 2026.
- Business Quant data shows ATNM's Accounts Payables at $6.6 million in Q1 2026, $7.2 million in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 8.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.51 Mn |
| Mar 31, 2026 | 6.62 Mn |
| Dec 31, 2025 | 7.25 Mn |
| Sep 30, 2025 | 6.22 Mn |
| Jun 30, 2025 | 7.71 Mn |
| Mar 31, 2025 | 6.52 Mn |
| Dec 31, 2024 | 7.57 Mn |
| Sep 30, 2024 | 7.20 Mn |
| Jun 30, 2024 | 9.18 Mn |
| Dec 31, 2023 | 7.95 Mn |
| Dec 31, 2020 | 4.34 Mn |
| Sep 30, 2020 | 4.22 Mn |
| Jun 30, 2020 | 4.09 Mn |
| Dec 31, 2019 | 4.60 Mn |
| Sep 30, 2019 | 5.13 Mn |
| Jun 30, 2019 | 4.70 Mn |
| Mar 31, 2019 | 5.32 Mn |
| Dec 31, 2018 | 5.81 Mn |
| Sep 30, 2018 | 4.12 Mn |
| Jun 30, 2018 | 5.27 Mn |